Latest news with #Kopran
Business Standard
15-05-2025
- Business
- Business Standard
Kopran consolidated net profit declines 48.01% in the March 2025 quarter
Sales decline 7.37% to Rs 172.36 crore Net profit of Kopran declined 48.01% to Rs 9.68 crore in the quarter ended March 2025 as against Rs 18.62 crore during the previous quarter ended March 2024. Sales declined 7.37% to Rs 172.36 crore in the quarter ended March 2025 as against Rs 186.08 crore during the previous quarter ended March 2024. For the full year,net profit declined 24.35% to Rs 38.55 crore in the year ended March 2025 as against Rs 50.96 crore during the previous year ended March 2024. Sales rose 2.44% to Rs 629.60 crore in the year ended March 2025 as against Rs 614.59 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 172.36186.08 -7 629.60614.59 2 OPM % 9.9211.66 - 11.5812.11 - PBDT 17.5828.77 -39 67.5480.43 -16 PBT 13.7125.18 -46 51.9567.54 -23 NP 9.6818.62 -48 38.5550.96 -24
Business Standard
28-04-2025
- Business
- Business Standard
Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly
Kopran climbed 4.39% to Rs 198.35 after the company announced a successful closure of a US drug regulator's inspection at its subsidiary's API facility. The United States Food and Drug Administration (USFDA) recently carried out a surveillance inspection at Kopran Research Laboratories, the companys wholly owned subsidiary. The inspection was conducted at the API manufacturing unit located in Mahad, Maharashtra, between April 21 and April 25, 2025. In a regulatory filing, Kopran confirmed that the inspection was concluded without any observations. Kopran is engaged in the business of manufacturing of formulation (finished dosage form). On a consolidated basis, net profit of Kopran declined 34.14% to Rs 10.40 crore while net sales rose 4.61% to Rs 166.24 crore in Q3 December 2024 over Q3 December 2023.
Time of India
26-04-2025
- Business
- Time of India
Madhusudan Kela bites this crunchy pick in Mar quarter, adds 2 more smallcaps to his Rs 3,500 cr portfolio
Ace investor Madhusudan Kela added three new smallcap stocks in his portfolio in the quarter ended March 31, 2025 viz. Windsor Machines , SG Finserve and Prataap Snacks while raising stakes in Kopran . Kela, who has a portfolio worth over Rs 3,500 crore according to data available on Trendlyne, holds 17 stocks as per the latest shareholding data compiled by it. Windsor Machines The injection moulding machine manufacturer has a market capitalisation of Rs 2,388 crore on the BSE . Kela bought 7.71% stake in the company. The stock is down 17% in 2025 so far but has had a stellar journey over the past one year, delivering multibagger returns of 248%. SG Finserve SG Finserve is a tech-enabled non-banking finance company (NBFC). The stock has fallen over 1% this year while declining 7% on the 1-year basis. He bought a 1.70% stake in the company. Live Events Prataap Snacks Kela bought 4.61% stake in the Prataap Snacks counter. The market capitalisation on the BSE stands at Rs 2,918.41 crore. Shares of Prataap Snacks have risen 8% so far this year while rallying 35% over a 1 year period. Kopran Kela increased his holding by 42 bps in Kopran, bringing his stake to 1.46% in the March ended quarter from 1.04% at the end of the December quarter. Kopran is an integrated pharmaceutical company based out of Mumbai. The company is a manufacturer and supplier of formulations and Active Pharmaceutical Ingredients (API), worldwide. Kopran's manufacturing facilities and products have accreditations in all the continents, the company website claims. The stock has been on a losing side falling by 11% and 25% on a year-to-date and one-year basis. Kela also has stakes in other stocks like Nazara Technologies , Samhi Hotels , Rashi Peripherals , Unicommerce eSolutions and Waaree Energies . Also Read: Dolly Khanna portfolio: Ace investor adds 2 new smallcaps in March quarter, raises stake in Som Distilleries, 6 others ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
